Top

Published in:

01-08-2018 | Therapy in Practice

BIM Deletion Polymorphism Confers Resistance to Osimertinib in EGFR T790M Lung Cancer: a Case Report and Literature Review

Authors: Xuanzong Li, Shijiang Wang, Butuo Li, Zhen Wang, Shuheng Shang, Yang Shao, Xindong Sun, Linlin Wang

Published in: Targeted Oncology | Issue 4/2018

Abstract

The third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib (AZD9291) has shown significant clinical efficacy against the EGFR T790M mutation in non-small cell lung cancer (NSCLC) patients. However, resistance inevitably occurs, and the mechanisms leading to treatment failure need to be further investigated. The B-cell lymphoma 2 (BCL-2)-like 11 (BIM) deletion polymorphism, which occurs at a frequency of 21% in East Asians but is absent in African and European populations, has been associated with resistance to first-generation EGFR TKIs, such as gefitinib and erlotinib; and is a poor prognostic factor for NSCLC patients with EGFR mutations. Nevertheless, the significance of this BIM deletion polymorphism in the resistance to osimertinib has not been reported. Here, we show for the first time that a NSCLC patient harboring the EGFR L858R/T790M mutations, as well as the BIM deletion polymorphism, exhibited poor clinical outcomes with osimertinib treatment. This result suggests that the BIM deletion polymorphism might have prognostic value for determining NSCLC patient outcomes following osimertinib treatment.

Available only for authorised users

Cross DAE, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discovery. 2014;4(9):1046–61. https://doi.org/10.1158/2159-8290.CD-14-0337.CrossRefPubMedPubMedCentral

Mok TS. Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS et al. Osimertinib or platinum-Pemetrexed in EGFR T790M-positive lung Cancer. N Engl J Med. 2017;376(7):629–40. https://doi.org/10.1056/NEJMoa1612674. CrossRefPubMed

Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung Cancer. N Engl J Med. 2018;378(2):113–25. https://doi.org/10.1056/NEJMoa1713137.CrossRefPubMed

Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015;21(6):560–2. https://doi.org/10.1038/nm.3854.CrossRefPubMedPubMedCentral

Yu HA, Tian SK, Drilon AE, Borsu L, Riely GJ, Arcila ME, et al. Acquired resistance of EGFR-mutant lung Cancer to a T790M-specific EGFR inhibitor: emergence of a third mutation (C797S) in the EGFR tyrosine kinase domain. JAMA Oncol. 2015;1(7):982–4. https://doi.org/10.1001/jamaoncol.2015.1066.CrossRefPubMedPubMedCentral

Niederst MJ, Hu H, Mulvey HE, Lockerman EL, Garcia AR, Piotrowska Z, et al. The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies. Clin Cancer Res. 2015;21(17):3924–33. https://doi.org/10.1158/1078-0432.ccr-15-0560.CrossRefPubMedPubMedCentral

Yang Z, Yang N, Ou Q, Xiang Y, Jiang T, Wu X, et al. Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients. Clin Cancer Res. 2018. https://doi.org/10.1158/1078-0432.ccr-17-2310.

Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 2008;9(1):47–59. https://doi.org/10.1038/nrm2308.CrossRefPubMed

Ng KP, Hillmer AM, Chuah CT, Juan WC, Ko TK, Teo AS, et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med. 2012;18(4):521–8. https://doi.org/10.1038/nm.2713.CrossRefPubMed

10.

Faber AC, Corcoran RB, Ebi H, Sequist LV, Waltman BA, Chung E, et al. BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. Cancer Discovery. 2011;1(4):352–65. https://doi.org/10.1158/2159-8290.cd-11-0106.CrossRefPubMedPubMedCentral

11.

Adachi M, Zhao X, Imai K. Nomenclature of dynein light chain-linked BH3-only protein Bim isoforms. Cell Death Differ. 2005;12(2):192–3. https://doi.org/10.1038/sj.cdd.4401529.CrossRefPubMed

12.

Zou Q, Zhan P, Lv T, Song Y. The relationship between BIM deletion polymorphism and clinical significance of epidermal growth factor receptor-mutated non-small cell lung cancer patients with epidermal growth factor receptor-tyrosine kinase inhibitor therapy: a meta-analysis. Trans Lung Cancer Res. 2015;4(6):792–6. https://doi.org/10.3978/j.issn.2218-6751.2015.12.09. CrossRef

13.

Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczesna A, Juhasz E, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010;11(6):521–9. https://doi.org/10.1016/s1470-2045(10)70112-1.CrossRefPubMed

14.

Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, et al. Non-small cell lung Cancer, version 6. J Ntnl Comprehens Cancer Netw. 2015;13(5):515–24.CrossRef

15.

Yang JC, Ahn MJ, Kim DW, Ramalingam SS, Sequist LV, Su WC, et al. Osimertinib in pretreated T790M-positive advanced non-small-cell lung Cancer: AURA study phase II extension component. J Clin Oncol. 2017;35(12):1288–96. https://doi.org/10.1200/jco.2016.70.3223.CrossRefPubMed

16.

Planchard D, Loriot Y, Andre F, Gobert A, Auger N, Lacroix L, et al. EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients. Ann Oncol. 2015;26(10):2073–8. https://doi.org/10.1093/annonc/mdv319.CrossRefPubMed

17.

Ou SI, Agarwal N, Ali SM. High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression. Lung Cancer. 2016;98:59–61. https://doi.org/10.1016/j.lungcan.2016.05.015.CrossRefPubMed

18.

Cragg MS, Kuroda J, Puthalakath H, Huang DC, Strasser A. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med. 2007;4(10):1681–9. https://doi.org/10.1371/journal.pmed.0040316. CrossRefPubMed

19.

Nakagawa T, Takeuchi S, Yamada T, Ebi H, Sano T, Nanjo S, et al. EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition. Cancer Res. 2013;73(8):2428–34. https://doi.org/10.1158/0008-5472.can-12-3479.CrossRefPubMed

20.

Costa DB, Halmos B, Kumar A, Schumer ST, Huberman MS, Boggon TJ, et al. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med. 2007;4(10):1669–79. https://doi.org/10.1371/journal.pmed.0040315. CrossRefPubMed

21.

Rosell R, Bivona TG, Karachaliou N. Genetics and biomarkers in personalisation of lung cancer treatment. Lancet. 2013;382(9893):720–31. https://doi.org/10.1016/s0140-6736(13)61715-8.CrossRefPubMed

22.

Ebi H, Oze I, Nakagawa T, Ito H, Hosono S, Matsuda F, et al. Lack of association between the BIM deletion polymorphism and the risk of lung cancer with and without EGFR mutations. J Thorac Oncol. 2015;10(1):59–66. https://doi.org/10.1097/jto.0000000000000371.CrossRefPubMed

23.

Lee JH, Lin YL, Hsu WH, Chen HY, Chang YC, Yu CJ, et al. Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer. J Thorac Oncol. 2014;9(9):1385–92. https://doi.org/10.1097/jto.0000000000000238.CrossRefPubMed

24.

Soh SX, Siddiqui FJ, Allen JC, Kim GW, Lee JC, Yatabe Y, et al. A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer. Oncotarget. 2017;8(25):41474–86. https://doi.org/10.18632/oncotarget.17102. CrossRefPubMedPubMedCentral

25.

Atsumi J, Shimizu K, Ohtaki Y, Kaira K, Kakegawa S, Nagashima T, et al. Impact of the Bim deletion polymorphism on survival among patients with completely resected non-small-cell lung carcinoma. J Glob Oncol. 2016;2(1):15–25. https://doi.org/10.1200/jgo.2015.000638.CrossRefPubMed

26.

Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, et al. The IASLC lung Cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung Cancer. J Thorac Oncol. 2016;11(1):39–51. https://doi.org/10.1016/j.jtho.2015.09.009.CrossRefPubMed

27.

Isobe K, Hata Y, Tochigi N, Kaburaki K, Kobayashi H, Makino T, et al. Clinical significance of BIM deletion polymorphism in non-small-cell lung cancer with epidermal growth factor receptor mutation. J Thorac Oncol. 2014;9(4):483–7. https://doi.org/10.1097/jto.0000000000000125.CrossRefPubMedPubMedCentral

28.

Zhong J, Li ZX, Zhao J, Duan JC, Bai H, An TT, et al. Analysis of BIM (BCL-2 like 11 gene) deletion polymorphism in Chinese non-small cell lung cancer patients. Thoracic Cancer. 2014;5(6):509–16. https://doi.org/10.1111/1759-7714.12119.CrossRefPubMedPubMedCentral

29.

Zhao M, Zhang Y, Cai W, Li J, Zhou F, Cheng N, et al. The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer. Cancer. 2014;120(15):2299–307. https://doi.org/10.1002/cncr.28725. CrossRefPubMed

30.

Tanimoto A, Takeuchi S, Arai S, Fukuda K, Yamada T, Roca X, et al. Histone deacetylase 3 inhibition overcomes BIM deletion polymorphism-mediated Osimertinib resistance in EGFR-mutant lung Cancer. Clin Cancer Res. 2017;23(12):3139–49. https://doi.org/10.1158/1078-0432.ccr-16-2271.CrossRefPubMed

31.

Deng J, Shimamura T, Perera S, Carlson NE, Cai D, Shapiro GI, et al. Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion. Cancer Res. 2007;67(24):11867–75. https://doi.org/10.1158/0008-5472.can-07-1961.CrossRefPubMed

32.

Xia J, Bai H, Yan B, Li R, Shao M, Xiong L, et al. Mimicking the BIM BH3 domain overcomes resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer. Oncotarget. 2017;8(65):108522–33. https://doi.org/10.18632/oncotarget.19411. PubMedPubMedCentralCrossRef

Title: BIM Deletion Polymorphism Confers Resistance to Osimertinib in EGFR T790M Lung Cancer: a Case Report and Literature Review
Authors: Xuanzong Li
Shijiang Wang
Butuo Li
Zhen Wang
Shuheng Shang
Yang Shao
Xindong Sun
Linlin Wang
Publication date: 01-08-2018
Publisher: Springer International Publishing
Published in: Targeted Oncology / Issue 4/2018
Print ISSN: 1776-2596
Electronic ISSN: 1776-260X
DOI: https://doi.org/10.1007/s11523-018-0573-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2018

Growing Role of Regorafenib in the Treatment of Patients with Sarcoma

MicroRNAs as Mediators of Resistance Mechanisms to Small-Molecule Tyrosine Kinase Inhibitors in Solid Tumours

Coronary Toxicities of Anti-PD-1 and Anti-PD-L1 Immunotherapies: a Case Report and Review of the Literature and International Registries

Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors

The Role of Autophagy in the Resistance to BRAF Inhibition in BRAF-Mutated Melanoma

Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer